Complix and Jiangsu Nhwa to collaborate on treatment of CNS Diseases

pharmafile | July 28, 2021 | News story | Research and Development  

Complix has signed a global collaboration and license agreement with Jiangsu Nhwa Pharmaceutical Co, to develop Cell Penetrating Alphabodies (CPABs), able to cross the blood brain barrier, for the improved treatment of diseases of the central nervous system (CNS).

Complix and Nhwa will collaborate to develop novel biotherapeutics against two selected CNS targets.

Complix will apply its proprietary CPAB technology, that enables biologics to traverse membrane systems and act with high affinity and precision on disease targets that are considered intractable by current drug formats.

The novel compounds to be developed under this collaboration, will be designed to cross the blood brain barrier to address important disease targets in the central nervous system. 

Under the terms of the agreement, Complix has granted an exclusive license to Nhwa to develop, manufacture and commercialise the CPABs resulting from this collaboration in Greater China. Both companies retain joint development and commercialisation rights for these CPABs in the rest of the world.

Complix is entitled to upfront license payments and further milestone payments subject to the progress of clinical development and regulatory approval. Complix is also eligible for royalty payments based on the future commercial sales of the CPABs in China.

Mark Vaeck, CEO of Complix, said: “We are thrilled to announce this exciting collaboration with Nhwa. We are confident that the unique targeting capabilities of our CPABs will allow us to jointly develop novel biotherapeutics that will deliver improved treatment outcomes for patients suffering from severe neurological diseases.

“We believe that partnering with an innovative company like Nhwa, specialised in the area of CNS diseases, is substantially value creating, as it provides access to significant research and clinical development expertise in the CNS area, as well as a strong commercial platform in China.

“I am confident that together we can deliver on our ambitions to develop innovative and highly needed solutions for patients with severe neurological conditions”.

Lilly Subbotin

Related Content

No items found

Latest content